Date: 2015-04-09
Type of information: Nomination
Compound:
Company: Aegerion Pharmaceuticals (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 9, 2015, Aegerion Pharmaceuticals, a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, has appointed Jorge Plutzky, M.D., to its Board of Directors, effective immediately. Dr. Plutzky will serve as a Class I director and will be up for reelection to the Board of Directors in 2017. Dr. Plutzky will serve on the Nominating and Corporate Governance Committee of the Board. Dr. Plutzky was appointed to the Board as an independent director pursuant to a Nomination and Standstill Agreement with Sarissa Capital Management LP and related funds.
Dr. Plutzky is the Director of Preventive Cardiology, which includes the Lipid/Prevention Clinic, in the Cardiovascular Medicine Division at Brigham and Women\'s Hospital. Since 1995, he has been on the faculty at Harvard Medical School and he continues to direct his own NIH-funded basic science laboratory. Dr. Plutzky has been a member of the scientific advisory boards of the Sarnoff Cardiovascular Research Foundation since 2009, where he is now Chair Elect, a member of the American Society for Clinical Investigation and is a Fellow of the American College of Cardiology.
Dr. Plutzky currently serves as a member of the Board of Directors of VIVUS, Inc. He holds a B.A. from the University of Virginia, which he received with Highest Honors, and an M.D. from the University of North Carolina, Chapel Hill. He completed research fellowships at the National Institutes of Health and the Massachusetts Institute of Technology.
Financial terms:
Latest news:
